53
Participants
Start Date
May 1, 2024
Primary Completion Date
August 31, 2027
Study Completion Date
December 31, 2027
Tagraxofusp (Cycles 1-2)
12 mcg/kg intravenously Days 1-5
Azacitidine
75 mg/m2 intravenously Days 1-7 (Cycle 3-12)
Tagraxofusp (Cycles 3-12)
12 mcg/kg intravenously Days 1-3
RECRUITING
Roswell Park Cancer Institute, Buffalo
RECRUITING
Penn Medicine Abramson Cancer Center, Philadelphia
RECRUITING
Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
RECRUITING
University of North Carolina at Chapel Hill, Chapel Hill
RECRUITING
AdventHealth Orlando, Orlando
RECRUITING
University of Miami, Miami
RECRUITING
Lifespan Health System Rhode Island Hospital, Providence
Stemline Therapeutics, Inc.
INDUSTRY
University of North Carolina, Chapel Hill
OTHER
Joshua Zeidner
OTHER